Drugs / CG-549
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05393856 | Sep 2019 → Jan 2020 | — | CrystalGenomics, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CG-549 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05393856 ↗ |
| Route | Oral | “single oral dose of 300 mg CG-549 on Day 1” NCT05393856 ↗ |